Related Experiment Video
Updated: May 6, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
The Hype and the Hope: Where Do We Stand with Prostate-specific Membrane Antigen-targeted Fluorescence-guided
Vera A Ottens1, Giuseppe Chiarelli2, Roberto Contieri3
1Netherlands Cancer Institute, Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The Netherlands; Interventional Molecular Imaging Laboratory, Leiden University Medical Centre, Leiden, The Netherlands.
Abstract:
Early studies highlight the promise of prostate-specific membrane antigen-targeted fluorescence-guided surgery. Realization of the full potential of this strategy will require ongoing technical refinement and the integration of hybrid-guided approaches, supported by high-quality clinical evidence, to translate feasibility into meaningful oncological benefits.
Insights
Prostate-specific membrane antigen-targeted fluorescence-guided surgery shows early promise. Further technical improvements and clinical evidence are needed to maximize its oncological benefits.
Area of Science:
- Oncology
- Surgical Innovation
- Medical Imaging
Background:
- Prostate-specific membrane antigen (PSMA) is a promising target for cancer diagnostics and therapeutics.
- Fluorescence-guided surgery (FGS) offers real-time visualization to improve surgical precision.
- Early research indicates potential for PSMA-targeted FGS in various oncological procedures.

